Orthovita Rhakoss
This article was originally published in The Gray Sheet
Executive Summary
Orthopedic biomaterials manufacturer plans to file for a CE mark by year end, following completed enrollment of 70 cervical spinal fusion patients in a nine-site pivotal trial. Patients will be followed for six months. The synthetic bone spinal implant is a potentially safer alternative to allograft for cervical spinal fusion surgery, Orthovita contends (1"The Gray Sheet" Aug. 26, 2002, p. 28)...